2026-01-15T13:08:50+00:00 2025-03-31 346565596 ERNST & YOUNG US LLP 560 MISSION STREET SAN FRANCISCO CA 941052907 990 2024-04-01 751835298 The Susan G Komen Breast Cancer Foundation Inc SUSA 9728551600 13770 NOEL ROAD SUITE 801889 DALLAS TX 75380 RIA WILLIAMS CHIEF FINANCIAL OFFCIER 9728551600 2026-01-15 true Eva Nitta P01286320 4158948000 2026-01-15 2024 2025-03-06 01:10:19Z SUSAN G KOMEN RIA WILLIAMS 13770 NOEL ROAD SUITE 801889 DALLAS TX 75380 138937712 false X WWW.KOMEN.ORG X 1982 TX OUR MISSION IS TO SAVE LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER. 19 19 482 9977 8698 0 98107413 102783181 0 11825383 6255060 -6998610 -5883862 102934186 103154379 22270944 18581010 0 47674560 51571757 1364005 2054814 26593861 40180095 38289701 111489604 110497282 -8555418 -7342903 188139545 178872555 58636745 54765664 129502800 124106891 SUSAN G. KOMEN HAS AN UNMATCHED, COMPREHENSIVE 360-DEGREE APPROACH TO FIGHTING BREAST CANCER ACROSS ALL FRONTS AND SUPPORTING MILLIONS OF PEOPLE IN THE U.S. AND IN COUNTRIES WORLDWIDE. WE ADVOCATE FOR POLICIES TO PROTECT PATIENTS, DRIVE RESEARCH BREAKTHROUGHS, IMPROVE ACCESS TO HIGH-QUALITY CARE, OFFER DIRECT PATIENT NAVIGATION AND SUPPORT SERVICES AND EMPOWER PEOPLE WITH TRUSTWORTHY INFORMATION. KOMEN REMAINS COMMITTED TO SUPPORTING THOSE AFFECTED BY BREAST CANCER TODAY, WHILE TIRELESSLY SEARCHING FOR TOMORROW'S CURES. false false 47390113 7687029 0 PATIENT CARE: PROVISION OF BREAST HEALTH EDUCATION, BREAST CANCER PATIENT NAVIGATION SERVICES, AND FINANCIAL ASSISTANCE DIRECTLY BY KOMEN TO SUPPORT ACCESS TO SCREENING, DIAGNOSIS, AND TREATMENT PROGRAMS AS WELL AS GRANTS TO OTHER NON-PROFIT ORGANIZATIONS AND THIRD-PARTY CONTRACTS, WITH A FOCUS ON SERVING COMMUNITIES WHERE DISPARITIES IN OUTCOMES ARE SIGNIFICANT AND/OR ACCESS IS LIMITED. SEE SCHEDULE O FOR ADDITIONAL DETAILS. 18085047 10893941 0 RESEARCH: KOMEN-LED RESEARCH & SCIENTIFIC PROGRAMS AND GRANTS AWARDED TO RESEARCH INSTITUTIONS AND OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER RESEARCH PROJECTS INCLUDING THOSE FOCUSED-ON RESEARCH PRIORITIES THAT WILL MAKE THE BIGGEST DIFFERENCE FOR PATIENTS: CONQUERING METASTATIC AND AGGRESSIVE BREAST CANCERS, ADVANCING PERSONALIZED BREAST CARE AND ELIMINATING BREAST CANCER DISPARITIES TO IMPROVE OUTCOMES FOR EVERYONE IMPACTED BY BREAST CANCER. SEE SCHEDULE O FOR ADDITIONAL DETAILS. 5753937 0 0 PUBLIC POLICY AND ADVOCACY: BREAST CANCER-RELATED INITIATIVES THAT HAVE THE POTENTIAL TO IMPACT ALL PEOPLE, INCLUDING ACTIVITIES ADVOCATING FOR LEGISLATIVE, REGULATORY AND OTHER POLICY SOLUTIONS DESIGNED TO SUPPORT KEY PATIENT PROTECTIONS, ENSURE ACCESS TO HIGH-QUALITY AFFORDABLE CARE, ALLEVIATE FINANCIAL AND ADMINISTRATIVE BURDENS AND FUND CRITICAL BREAST CANCER RESEARCH. SEE SCHEDULE O FOR DETAILS. 71229097 true true false true false false false false false true true true false false false true false true false false true true false true true false false true true true false false false false false false false false false false true false false false false false false false false false true 245 0 true 482 true true true false false false false true true false false false false false false X 19 19 false false true false false false false true true false true true true true true true true true true true false false CA CO CT DE DC FL GA AL HI IL IN KS KY LA ME AK MD MA MI MN MS MO MT NH NJ NM NY NC ND OH OK OR PA AZ RI SC TN UT VT VA AR WA WV WI X X RIA WILLIAMS 9728551600 13770 NOEL ROAD SUITE 801889 DALLAS TX 75380 Ed Dandridge Chair of the Board 1.0 0 X X 0 0 0 Jerri Johnson Vice Chair 1.0 0 X X 0 0 0 BJ Schaknowski BOD Member 1.0 0 X 0 0 0 Boris Dolgonos BOD Member (ending March 2025) 1.0 0 X 0 0 0 Charles Rockefeller BOD Member 1.0 0 X 0 0 0 Christina Minnis BOD Member 1.0 0 X 0 0 0 Elizabeth Saint-Aignan BOD Member 1.0 0 X 0 0 0 Gail Heimann BOD Member 1.0 0 X 0 0 0 Julie Gruber BOD Member 1.0 0 X 0 0 0 Kathy Sutherland BOD Member 1.0 0 X 0 0 0 Kim Blackwell BOD Member 1.0 0 X 0 0 0 Kristen Maple BOD Member (ending March 2025) 1.0 0 X 0 0 0 Luke Sauter BOD Member 1.0 0 X 0 0 0 Lydia The BOD Member (ending March 2025) 1.0 0 X 0 0 0 Michelle Bottomley BOD Member 1.0 0 X 0 0 0 Paige Ross BOD Member (beginning March 2025) 1.0 0 X 0 0 0 Peter Brundage BOD Member 1.0 0 X 0 0 0 Robyn Shepherd BOD Member 1.0 0 X 0 0 0 Valerie Rainey BOD Member 1.0 0 X 0 0 0 Eunice Nakamura General Counsel and Corporate Secretary (Ending Feb-2025) 55.0 0 X 311206 0 24533 Paula Schneider President and CEO 55.0 0 X 658115 0 30697 Ria Williams Chief Financial Officer 55.0 0 X 323478 0 36314 Catherine Olivieri SVP, Human Resources 55.0 0 X 270792 0 27128 Kathryn Watt SVP, Community Development & Operations 55.0 0 X 265455 0 29529 Sarah Rosales VP, Corporate Partnerships 55.0 0 X 259602 0 32314 Victoria Smart SVP, Mission 55.0 0 X 265909 0 2935 Barbara Ducharme VP, CD Strategy & Midwest Region 55.0 0 X 202930 0 25211 Kimberly Sabelko VP, Research & Scientific Programs 55.0 0 X 203350 0 14396 Megan Klink VP, CD Strategy & West Region 55.0 0 X 201262 0 12414 Nicholas Michael DiFranza VP, Information Technology 55.0 0 X 254431 0 2492 Timothy A Newman VP, CD Strategy & South Region 55.0 0 X 198810 0 7916 3415340 0 245879 129 false true false Event 360 205 N Michigan Ave Chicago IL 60601 Event Management 2149613 RKD Group LLC 3400 Waterview Parkway Richardson TX 75080 Consulting 633980 Splick 13 Assoc DBA Reinvent the World 33 Aldridge Rd Chappaque NY 10514 Fundraising consulting 355342 Ernst & Young 2323 Victory Avenue Suite 2000 Dallas TX 75219 Acctg & Tax Services 340920 Dana-Farber Cancer Institute Inc 450 Brookline Avenue Mailstop BP437 Boston MA 022155450 PROGRAM SERVICES 309665 16 241281 0 34977518 0 0 67564382 603114 102783181 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2374124 0 0 2374124 0 0 0 0 51000 0 0 51000 0 0 0 0 0 0 0 0 0 0 30989495 0 27108559 0 3880936 0 3880936 0 0 3880936 2460355 34977518 8635082 -6174727 0 -6174727 8231 0 8231 0 0 8231 112692 39692 73000 0 0 73000 OTHER INCOME 900099 158634 0 8698 149936 0 0 0 0 0 0 0 0 0 0 0 0 158634 103154379 0 8698 362500 10964376 10964376 7471750 7471750 144884 144884 0 0 2538009 1653509 294221 590279 0 0 0 0 40350074 21851797 7917235 10581042 1707373 958344 300413 448616 4030049 2147223 908497 974329 2946252 1604498 559989 781765 0 0 0 0 188069 73231 42032 72806 361235 34076 327159 0 375932 375932 0 0 2054814 2054814 0 0 0 0 0 0 0 0 6579739 4781285 273846 1524608 13459606 6813506 89048 6557052 2369416 1018849 687131 663436 0 0 0 0 155237 112292 2877 40068 983085 557954 131845 293286 0 0 0 0 222033 149405 17195 55433 0 0 0 0 0 0 0 0 1289614 1158773 66729 64112 467923 350942 0 116981 CONSULT & PROF. FEES 5305493 4464720 460553 380220 EQUIP RENTAL & MAINT 3317081 2547293 288391 481397 MERCHANT SERVICES & BANK FEES 1925997 1212895 78514 634588 EVENT PRODUCTION 408323 313754 15131 79438 880918 467809 213518 199591 110497282 71229097 12674324 26593861 47650051 33080905 1338884 13230262 0 0 16541435 12163457 15796832 18486634 0 0 0 0 0 0 0 0 15990 21168 2007298 2261620 14371860 11541722 3645416 2830138 114278903 106384407 33480000 34020000 0 0 0 2373671 2705131 188139545 178872555 6826023 8934393 51574727 45550351 235995 280920 0 0 0 0 0 0 0 0 0 0 0 0 58636745 54765664 88459438 84977043 41043362 39129848 0 0 0 0 0 0 129502800 124106891 188139545 178872555 X -7342903 1162055 98668 -419170 0 1105441 X false true true false X 50983746 99456148 111805407 98107413 102783181 463135895 0 0 50983746 99456148 111805407 98107413 102783181 463135895 10491781 452644114 1217543 1156360 1438781 12830552 2425124 19068360 0 15070 3574 26758 50721 149936 246059 482450314 44646371 0.93822 0.92261 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - OTHER INCOME, COLUMN A - 15070.0, COLUMN B - 3574.0, COLUMN C - 26758.0, COLUMN D - 50721.0, COLUMN E - 149936.0, COLUMN F - 246059.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 25410 25410 350522 350522 375932 375932 97447026 97447026 97822958 97822958 1000000 1000000 250000 250000 0 0 0 0 1000000 1000000 1000000 1000000 4000000 6000000 204997 293520 320990 375932 1195439 250000 250000 250000 250000 1000000 1500000 26906 15803 20317 25410 88436 Schedule C, Part II-A Lobbying Expenses PUBLIC POLICY AND ADVOCACY INITIATIVES HAVE THE POTENTIAL TO IMPACT ALL PEOPLE TOUCHED BY BREAST CANCER. RECOGNIZING THE IMPORTANCE OF THIS WORK TO ACCOMPLISH ITS MISSION, KOMEN SUPPORTS LIMITED LOBBYING ACTIVITIES TO ACHIEVE LEGISLATIVE AND REGULATORY SOLUTIONS DESIGNED TO SUPPORT KEY PATIENT PROTECTIONS, EXPAND ACCESS TO HIGH-QUALITY CARE AND FUND CRITICAL BREAST CANCER RESEARCH. 3626572 61376 10976 0 57866 0 3641058 3612548 133367 26029 0 145372 0 3626572 1346868 2279000 -7607 5713 3612548 1342173 0 10613 0 5918 0 1346868 1337562 0 10279 0 5668 0 1342173 0.28 0.71 0.01 false false 0 0 0 0 0 0 0 0 0 0 0 0 9497787 6966640 2531147 0 4874073 4575082 298991 2830138 0 0 Closely-held equity interests 0 Financial derivatives 0 PRIVATE EQUITY FUND 34020000 F 34020000 0 X 136501446 1162054 33790718 0 6587 34959359 101542087 419170 1193122 1612292 103154379 141924509 33692050 0 0 6589 33698639 108225870 0 2271412 2271412 110497282 Schedule D, Part V, Line 4 Intended uses of endowment funds KOMEN HAS FIVE PERMANENT ENDOWMENTS: GOODMAN-BRINKER, FIRNBERG, TWO GENERAL ENDOWMENTS, AND A PERPETUAL TRUST. THE GOODMAN-BRINKER ENDOWMENT IS FOR BREAST CANCER RESEARCH FELLOWSHIPS, THE FIRNBERG ENDOWMENT IS FOR BREAST CANCER EDUCATIONAL PROGRAMS AND RESEARCH AWARDS, THE GENERAL ENDOWMENT AND PERPETUAL TRUST'S EARNINGS ARE RESTRICTED FOR ORGANIZATIONAL MISSION ACTIVITIES. ADDITIONALLY, THERE IS ONE GENERAL ENDOWMENT FUND ESTABLISHED BY THE BOARD OF DIRECTORS. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote THE ORGANIZATION IS SUBJECT TO A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE WERE NO UNCERTAIN TAX POSITIONS RECORDED IN THE CONSOLIDATED FINANCIAL STATEMENTS AT MARCH 31, 2025 Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990 Program COGS - 6587 Schedule D, Part XI, Line 4(b) Other revenues in form 990 not in audited financial statements Fundraising expenses - 1166096 Revenue eliminated upon consolidation - 27026 Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990 PROGRAM COGS - 6587 Rounding - 2 Schedule D, Part XII, Line 4(b) Other expenses in form 990 not in audited financial statements Rescinded grants - 1105316 Fundraising expenses - 1166096 true Europe (Including Iceland and Greenland) 0 1 Grantmaking Research 59884 Europe (Including Iceland and Greenland) 0 1 Program Services Research 6639 Europe (Including Iceland and Greenland) 0 1 Program Services Learning Mgmt System 19292 Europe (Including Iceland and Greenland) 0 1 Program Services Mission Tool Development 30375 North America (Canada & Mexico only) 0 2 Program Services Mission Support 14725 North America (Canada & Mexico only) 0 1 Program Services Merchandise 37911 North America (Canada & Mexico only) 0 1 Grantmaking Research 75000 North America (Canada & Mexico only) 0 2 Program Services Software Licenses and Implementation 37066 Europe (Including Iceland and Greenland) 0 1 Grantmaking Patient Care / Education 10000 0 11 0 0 0 11 290892 0 290892 Europe (Including Iceland and Greenland) Research 59884 Wire 0 n/a FMV North America (Canada & Mexico only) Research 75000 wire 0 n/a fmv Europe (Including Iceland and Greenland) Patient Care/Education 10000 wire 0 n/a fmv 3 0 true false true false false false Schedule F, Part I, Line 2 Procedures for monitoring use of grant funds AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR GRANTS, ALL GRANTEES ARE REQUIRED TO SUBMIT PROGRESS REPORTS, FINANCIAL REPORTS AND ANY CHANGE REQUESTS THEY MAY HAVE FOR THEIR PROJECTS, IN THE FORMAT REQUIRED BY KOMEN AND IN ACCORDANCE WITH THE SCHEDULE SET FORTH IN THE POLICIES. ALL PROGRESS REPORTS AND REQUESTS ARE REVIEWED BY QUALIFIED STAFF. SEE SCHEDULE I, PART IV AND SCHEDULE O, PART IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS. Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual Schedule F, Part II, Line 1 Method used to account for expenditures on org's financial statements EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual X X X X X X true Revunami Inc 228 E 85th St Suite 9C New York NY 10028 Marketing Consultant false 0 34325 -34325 RKD Group LLC 3400 Waterview Parkway Suite 250 Richardson TX 75080 Fundraising Consultant false 17756548 316990 17439558 Event 360 Inc 55 E Jackson Blvd Suite1030 Chicago IL 60604 Event Fundraising false 10642566 537403 10105163 Kars-R-Uscom 6059 N Briargate Lane Glendora CA 91740 Fundraising true 1624516 1166096 458420 30023630 2054814 27968816 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY 3 Day Series 12944913 12768332 176581 0 1315 1908873 495980 0 1537237 Race-WalkEvents 20830989 19602289 1228700 0 266327 266534 341280 16262 2987665 3661971 2606897 1055074 0 31895 209579 238899 43779 289457 37437873 34977518 2460355 0 299537 2384986 1076159 60041 4814359 8635082 -6174727 Schedule G, Part II Net Income Summary Gross receipts are reduced by the amount of fundraising contributions, per IRS instructions. The contributions for fiscal year 2025 were $35 million. Schedule G, Part I, Line 2b(v) KARS-R-Us.com Fundraising The fundraising agreement between KARS-R-US.COM (the fundraiser) and Susan G. Komen (the charity) provides for the fundraiser to accept and liquidate donated vehicles, vessels and other items of value on behalf (the units) of the charity without charge. The fundraiser charges the charity for the 50% of the cost of advertising plus a fee for each unit donated and sold. The fundraiser deducts these costs from the gross sale price less direct costs to determine the net proceeds from each unit sold. The charity and the fundraiser each receive 50% of the net proceeds, which were $458,420. Advertising and per unit fees totaled $707,676 for FY25. Schedule G, Part I, Line 2b(ii) Describe the custody or control arrangement. KARS-R-US.COM-FUNDRAISER ACCEPTS AND LIQUIDATES DONATED VEHICLES, VESSELS, AND OTHER ITEMS OF VALUE ON BEHALF OF SUSAN G. KOMEN AND DEDUCTS FROM THE PROCEEDS OF SALES THEIR FEES.; true Albert Einstein College of Med Yeshiva U 1300 Morris Park AvenueBelfer 1108 Bronx NY 104611975 131624225 501(c)(3) 229500 0 FMV N/A Research Baptist Memorial Health Care Foundation 350 N Humphreys Blvd Memphis TN 38120 581544781 501(c)(3) 2681 0 FMV N/A Patient Care Barnes-Jewish Hospital Attn Bryan Linck 4249 Clayton Aven St Louis MO 63110 237309937 501(c)(3) 37500 0 FMV N/A Patient Care Baylor College Medicine Grants - Accounts Receivable One Ba Houston TX 770303411 741613878 501(c)(3) 326549 0 FMV N/A Research Boston University 580 Harrison Avenue 3-W Boston MA 02118 042103547 501(c)(3) 179998 0 FMV N/A Research Brigham and Women's Hospital Attn Jeffrey Rivera 181 Longwood A Boston MA 02115 042312909 501(c)(3) 103993 0 FMV N/A Research Case Western Reserve University Controllers Office 10900 Euclid Av Cleveland OH 441067006 341018992 501(c)(3) 75000 0 FMV N/A Research Columbia University Medical Center 722 West 168th Street 4th Floor New York NY 10032 135598093 501(c)(3) 75000 0 FMV N/A Research Columbia University Medical Center Sponsored Projects Finance 615 West New York NY 100270000 135598093 501(c)(3) 100000 0 FMV N/A Research Dana Farber Cancer Institute 44 Binney Street Mail Stop 439C Boston MA 02115 042263040 501(c)(3) 70000 0 FMV N/A Research Dana-Farber Cancer Institute Inc 450 Brookline Avenue BP 412 Boston MA 022155450 042263040 501(c)(3) 729735 0 FMV N/A Research Dana-Farber Cancer Institute 44 Binney Street Mail Stop 439C Boston MA 02115 042263040 501(c)(3) 870000 0 FMV N/A Research Duke University Medical Center PO Box 602651 Charlotte NC 282602651 560532129 501(c)(3) 589097 0 FMV N/A Research Emory University 1599 Clifton Road NE 4th Floor Mai Atlanta GA 303224250 580566256 501(c)(3) 158660 0 FMV N/A Research Indiana U (Indianapolis) Financial Mgmt Svcs PO Box 66057 Indianapolis IN 462666057 356001673 501(c)(3) 458619 0 FMV N/A Research Indiana University (Indianapolis) Financial Mgmt Svcs PO Box 66057 Indianapolis IN 462666057 356001673 501(c)(3) 834515 0 FMV N/A Research Johns Hopkins University 1650 Orleans Street Suite 141 Baltimore MD 21231 520595110 501(c)(3) 937500 0 FMV N/A Research Johns Hopkins U 1101 East 33rd Street Eastern C220 Baltimore MD 21218 520595110 501(c)(3) 180000 0 FMV N/A Research Leland Stanford Jr University 485 Broadway Mail Code 8838 Redwood City CA 94063 941156365 501(c)(3) 100000 0 FMV N/A Research Loyola University Chicago 820 N Michigan Avenue Suite 1300 Chicago IL 60611 361408475 501(c)(3) 56187 0 FMV N/A Research Mayo Clinic Jacksonville Griffin Building Room 170 4500 San Jacksonville FL 32224 593337028 501(c)(3) 100000 0 FMV N/A Research Memorial Sloan-Kettering Cancer Ctr 1275 York Ave New York NY 10065 131924236 501(c)(3) 375000 0 FMV N/A Research Michigan State University Contract Grant Administration 301 East Lansing MI 48824 386005984 501(c)(3) 60832 0 FMV N/A Research Oregon Health & Science University 0690 SW Bancroft Mail Code L106SPA Portland OR 97239 931176109 501(c)(3) 289999 0 FMV N/A Research Parkland Foundation 2777 North Stemmons Freeway Suite 1 Dallas TX 75207 752089180 501(c)(3) 150000 0 FMV N/A Patient Care Ponce Medical School Foundation Inc 388 Dr Luis F Sala St Ponce PR 007162347 660379122 501(c)(3) 62374 0 FMV N/A Research Princeton University 701 Carnegie Center Princeton NJ 08540 210634501 501(c)(3) 200000 0 FMV N/A Research Recinto de Ciencias Medicas PO Box 365067 San Juan PR 009365067 660433762 501(c)(3) 97866 0 FMV N/A Research Regents of University of Michigan Room 7110 CCGC Internal Med 3003 Ann Arbor MI 481091274 386006309 501(c)(3) 75000 0 FMV N/A Research Rockefeller University Attn Shawn Davis Ofc of Developme New York NY 10065 131624158 501(c)(3) 100000 0 FMV N/A Research Roswell Park Alliance Foundation Department of Immunology Elm Carl Buffalo NY 14263 161391608 501(c)(3) 340531 0 FMV N/A Research Stanford University' PO Box 44253 San Francisco CA 941444253 941156365 501(c)(3) 448168 0 FMV N/A Research Texas A&M Univ System HSC-Research Fdn Attn Michele Kent 3578 TAMU College Station TX 778433578 746000541 501(c)(3) 39578 0 FMV N/A Research The Massachusetts General Hospital 55 Fruit St Boston MA 021142696 042697983 501(c)(3) 100000 0 FMV N/A Research The Ohio State University College Attn Kathy Milem 700 Childrens Dr Columbus OH 43205 316025986 501(c)(3) 530919 0 FMV N/A Research The Salk Institute Attn Christine Marckese 10010 Nort La Jolla CA 920371002 952160097 501(c)(3) 150000 0 FMV N/A Research The University of Chicago 6030 S Ellis AvenueRM 114 Chicago IL 60637 362177139 501(c)(3) 100000 0 FMV N/A Research The University of Texas at Austin Communications Career Services 300 Austin TX 78712 746000203 501(c)(3) 56799 0 FMV N/A Research Univ of North Carolina at Chapel Hill 104 Airport Drive Suite 2200 CB Chapel Hill NC 275991350 566001393 501(c)(3) 945992 0 FMV N/A Research Univ of Texas MD Anderson Cancer Center Grants Contracts PO Box 4390 Houston TX 772104390 746001118 501(c)(3) 600000 0 FMV N/A Research University Hospitals Cleveland Medical 11100 Euclid Avenue Cleveland OH 44106 341567805 501(c)(3) 225000 0 FMV N/A Research University of Alabama at Birmingham 1530 3rd Avenue South Administratio Birmingham AL 352940111 636005396 501(c)(3) 60000 0 FMV N/A Research University of California at San Francis' Andrew Boulter 3333 California St San Francisco CA 94118 946036493 501(c)(3) 320000 0 FMV N/A Research University of California-Davis Cashiers Office PO Box 989062 West Sacramento CA 957989062 946036494 501(c)(3) 100000 0 FMV N/A Research University of Chicago Attn Michael Ludwig 5801 S Ellis Chicago IL 60637 362177139 501(c)(3) 179550 0 FMV N/A Research University of Illinois at Chicago PO Box 20787 Springfield IL 627080787 376000511 501(c)(3) 100000 0 FMV N/A Research University of Kansas Medical Center Attn Tim Siskey 3901 Rainbow Boul Kansas City KS 66160 481108830 501(c)(3) 78257 0 FMV N/A Research University of North Carolina 104 Airport Drive Suite 2200 CB Chapel Hill NC 275999525 566001393 501(c)(3) 180000 0 FMV N/A Research University of Notre Dame du Lac 836a Grace Hall Notre Dame IN 465565612 350868188 501(c)(3) 50000 0 FMV N/A Research University of Pennsylvania Office of Research Services 3451 Wa Philadelphia PA 191046205 231352685 501(c)(3) 473675 0 FMV N/A Research University of Pittsburgh' Office of Budget Controller 4200 Pittsburgh PA 15260 250965591 501(c)(3) 300000 0 FMV N/A Research University of Utah 201 South Presidents Circle Room Salt Lake City UT 841129020 876000525 501(c)(3) 300000 0 FMV N/A Research University of Virginia at School of Medi PO Box 400195 Charlottesville VA 229044195 546001796 501(c)(3) 50000 0 FMV N/A Research University of Wisconsin - Madison Research Sponsored Programs 21 No Madison WI 537151218 396006492 501(c)(3) 71493 0 FMV N/A Research UT Southwestern Medical Center' 5323 Harry Hines Boulevard Attn Da Dallas TX 753909020 746000203 501(c)(3) 560410 0 FMV N/A Research UTMD Anderson Cancer Ctr 1515 Holcombe Boulevard Unit 1644 Houston TX 770304009 746001118 501(c)(3) 15000 0 FMV N/A Research Vanderbilt University Medical Center 3319 West End Ave Suite 970 Atlanta GA 372036856 620476822 501(c)(3) 721137 0 FMV N/A Research Virginia Commonwealth University 800 E Leigh St Suite 3100 Richmond VA 232843039 546001758 501(c)(3) 155699 0 FMV N/A Research Washington University at St Louis Scho Nicole Nichols/Sarah Gehlert 660 S St Louis MO 63110 430653611 501(c)(3) 328106 0 FMV N/A Research Weill Medical College of Cornell Univ 1300 York Avenue New York NY 10061 131623978 501(c)(3) 520000 0 FMV N/A Research Yale University' Office of Sponsored Projects 25 Sci New Haven CT 065208327 060646973 501(c)(3) 365000 0 FMV N/A Research 61 0 Patient Care Assistance @ $500 2621 1310500 0 fmv n/a Patient Care Assistance @ $750 1071 803250 0 fmv n/a Patient Care Assistance @ $400 13395 5358000 0 fmv n/a Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds SUSAN G. KOMEN'S (KOMEN) POLICIES FOR MANAGING GRANTS FROM THE TIME OF PRE-AWARD THROUGH CLOSEOUT ARE DESIGNED TO MAXIMIZE FLEXIBILITY WHILE MAINTAINING A HIGH STANDARD OF ACCOUNTABILITY AND PRESERVING THE INTEGRITY OF THE REVIEW AND AWARD PROCESS. KOMEN REQUIRES ALL GRANTEES TO SIGN A GRANT AGREEMENT SETTING FORTH THE TERMS OF THE GRANT, INCLUDING: PURPOSE, AMOUNT, BUDGETARY RESTRICTIONS, DURATION, PAYMENT SCHEDULE, REPORTING REQUIREMENTS, AUDIT, AND EARLY TERMINATION RIGHTS. FOR RESEARCH GRANTS, SCIENTIFIC PROGRESS AND FINANCIAL OVERSIGHT ARE MONITORED THROUGHOUT THE GRANT TERM BY A PH.D.-LEVEL RESEARCH GRANT MANAGER. FOR PATIENT CARE, EDUCATIONAL OR COMMUNITY PROGRAM GRANTS, PROGRESS AND FINANCIAL OVERSIGHT ARE MONITORED THROUGHOUT THE GRANT TERM BY QUALIFIED PROFESSIONALS SERVING AS GRANT MANAGERS. AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR GRANTS, GRANTEES ARE REQUIRED TO SUBMIT PROGRESS AND FINANCIAL REPORTS DETAILING PROGRESS TOWARD AIMS AND OBJECTIVES, MAJOR ACCOMPLISHMENTS, KEY DELIVERABLES AND CHALLENGES ENCOUNTERED, WITH A FULL ACCOUNTING OF GRANT FUNDS EXPENDED (ACTUAL VERSUS BUDGETED EXPENSES) AND WRITTEN JUSTIFICATION OF EXPENSES. AS APPROPRIATE, THE GRANTS MANAGER MAY CONDUCT SITE VISITS WITH GRANTEES TO GAIN A BETTER UNDERSTANDING OF THEIR WORK AND ADDRESS ANY CHALLENGES IMPACTING THE FUNDED PROGRAM. ALL GRANT FUNDS MUST BE EXPENDED IN ACCORDANCE WITH THE PROJECT'S APPROVED BUDGET AND ARE DISBURSED IN ACCORDANCE WITH THE SCHEDULE DOCUMENTED WITHIN THE GRANT AGREEMENT. REQUESTS FOR CHANGES TO THE DESIGN OF THE FUNDED PROJECT OR BUDGET ARE SUBJECT TO PRIOR APPROVAL BY KOMEN IN ACCORDANCE WITH THE TERMS OF THE GRANT AGREEMENT. AS PART OF ITS OVERSIGHT PRACTICES, THE TERMS OF THE GRANT AGREEMENT MAY PROVIDE KOMEN WITH, AMONG OTHER THINGS, THE RIGHT TO REQUEST WITH REASONABLE PRIOR NOTICE TO THE GRANTEE: (1) ADDITIONAL PROGRESS AND/OR FINANCIAL REPORTING FROM THE GRANTEE, (2) GRANTEE PARTICIPATION IN SITE VISITS, TELEPHONE CONFERENCES, PRESENTATIONS, OR OTHER SPEAKING ENGAGEMENTS, AND (3) WITH PRIOR WRITTEN NOTICE, ADJUSTMENT TO THE PROJECT REPORTING PERIOD AND ASSOCIATED DISBURSEMENT OF GRANT FUNDS AT ANY TIME DURING THE GRANT TERM. SEE SCHEDULE O, PART IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS. X X X X X X false false false false false false false false false Paula Schneider President and CEO 650216 0 0 0 7899 0 17436 0 13261 0 688812 0 0 0 Ria Williams Chief Financial Officer 320735 0 0 0 2743 0 20080 0 16234 0 359792 0 0 0 Eunice Nakamura General Counsel and Corporate Secretary (Ending Feb-2025) 308567 0 0 0 2639 0 15289 0 9244 0 335739 0 0 0 Catherine Olivieri SVP, Human Resources 268814 0 0 0 1978 0 16550 0 10578 0 297920 0 0 0 Victoria Smart SVP, Mission 264375 0 0 0 1534 0 0 0 2935 0 268844 0 0 0 Kathryn Watt SVP, Community Development & Operations 260576 0 0 0 4879 0 16378 0 13151 0 294984 0 0 0 Sarah Rosales VP, Corporate Partnerships 258236 0 0 0 1366 0 16398 0 15916 0 291916 0 0 0 Nicholas Michael DiFranza VP, Information Technology 252934 0 0 0 1497 0 0 0 2492 0 256923 0 0 0 Barbara Ducharme VP, CD Strategy & Midwest Region 200795 0 0 0 2135 0 12206 0 13005 0 228141 0 0 0 Kimberly Sabelko VP, Research & Scientific Programs 199117 0 0 0 4233 0 11604 0 2792 0 217746 0 0 0 Megan Klink VP, CD Strategy & West Region 199845 0 0 0 1417 0 10427 0 1987 0 213676 0 0 0 Timothy A Newman VP, CD Strategy & South Region 197199 0 0 0 1611 0 5957 0 1959 0 206726 0 0 0 X 104952 NONE 1 5400 Other 75 339716 Market value X Gift bags/Gift Cards 32 60418 Market value X Event Supplies 17 92628 Market value 0 false false false Schedule M, Part I Explanations of reporting method for number of contributions Food inventory - Food & Beverage Number of contributions Other - Gift bags/Gift Cards Number of contributions Other - Event Supplies Number of contributions Clothing and household goods - Number of Contributions Collectibles - Number of contributions of guitars Form 990, Part I, Line 6 VOLUNTEERS VOLUNTEERS SERVE IN A VARIETY OF WAYS, BUT THE GREATEST NUMBERS OF VOLUNTEERS ASSIST WITH THE MORE THAN PINK WALKS, RACE FOR THE CURE RUNS, THE SUSAN G. KOMEN 3 DAY SERIES, AND ADVOCACY PROGRAMS. Form 990, Part III, Line 4 Program service accomplishments SUSAN G. KOMEN'S MISSION IS TO SAVE LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER. KOMEN TAKES A 360 DEGREE APPROACH TO FIGHT BREAST CANCER THROUGH: - RESEARCH, TO DRIVE BREAKTHROUGHS THAT WILL BRING US NEW KNOWLEDGE AND ADVANCES IN CARE FOR ALL. -COMMUNITY HEALTH, TO EMPOWER PEOPLE WITH TRUSTWORTHY INFORMATION AND SUPPORT PEOPLE IN THEIR BREAST HEALTH JOURNEY THROUGH DIRECT SERVICES, COMMUNITY PROGRAMS AND HEALTH SYSTEMS PARTNERSHIPS. - AND PUBLIC POLICY, TO ADVOCATE FOR POLICIES CREATING SYSTEMIC AND LASTING CHANGES THAT WILL FUND AND FACILITATE RESEARCH, ALLEVIATE THE BURDEN ON PATIENTS, AND PROTECT ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL. KOMEN IS A LEADING GLOBAL BREAST CANCER ORGANIZATION, HAVING FUNDED MORE BREAST CANCER RESEARCH THAN ANY OTHER NONPROFIT OUTSIDE OF THE U.S. GOVERNMENT WHILE PROVIDING REAL-TIME HELP TO THOSE FACING THE DISEASE. SINCE ITS FOUNDING IN 1982, KOMEN HAS INVESTED OVER $1.1 BILLION IN BREAST CANCER RESEARCH IN MORE THAN 2800 GRANTS AND MORE THAN 500 CLINICAL TRIALS CONDUCTED BY THOUSANDS OF THE BEST AND BRIGHTEST RESEARCHERS ACROSS THE US AND AROUND THE WORLD. KOMEN HAS ALSO PROVIDED OVER $3.3 BILLION IN COMMUNITY INVESTMENT FOR PATIENT NAVIGATION, SCREENING, DIAGNOSIS, TREATMENT, EDUCATION, AND EMOTIONAL PSYCHOSOCIAL SUPPORT PROGRAMS SERVING MILLIONS OF PEOPLE IN MORE THAN 60 COUNTRIES WORLDWIDE AS WELL AS PUBLIC POLICY AND ADVOCACY EFFORTS AT THE FEDERAL, STATE, AND LOCAL LEVELS, EMPOWERING POLICYMAKERS WITH KNOWLEDGE TO ACT FOR LASTING, SYSTEMIC CHANGE. KOMEN WAS FOUNDED BY NANCY G. BRINKER, WHO PROMISED HER SISTER, SUSAN G. KOMEN, THAT SHE WOULD END THE DISEASE THAT CLAIMED SUZY'S LIFE. KOMEN REMAINS COMMITTED TO SUPPORTING THOSE AFFECTED BY BREAST CANCER TODAY, WHILE TIRELESSLY SEARCHING FOR TOMORROW'S CURES. RESEARCH SINCE ITS FOUNDING IN 1982, KOMEN'S RESEARCH INVESTMENTS HAVE CONTRIBUTED TO MANY MAJOR ADVANCES IN BREAST CANCER SCIENCE. THE PROGRESS HAS BEEN SIGNIFICANT - TODAY, WE KNOW THAT BREAST CANCER IS MORE THAN A SINGLE DISEASE. WE HAVE A BETTER UNDERSTANDING OF THE GENETICS OF BREAST CANCER AND THE CRITICAL NEED TO TAILOR SCREENING, DIAGNOSIS, TREATMENT, AND PREVENTION STRATEGIES TO INDIVIDUALS THROUGH ADVANCES IN PRECISION MEDICINE. AND WE HAVE A BETTER UNDERSTANDING OF THE MANY FACTORS CONTRIBUTING TO DISPARITIES IN BREAST CANCER CARE AND OUTCOMES AND HOW TO ADDRESS/ELIMINATE THEM TO IMPROVE OUTCOMES FOR EVERYONE IMPACTED BY BREAST CANCER. KOMEN'S RESEARCH PROGRAMS ARE ADDRESSING CRITICAL ISSUES AND CUTTING-EDGE TOPICS THAT WILL DRIVE PROGRESS AND PROVIDE THE GREATEST BENEFIT TO PATIENTS. THE PATIENT VOICE IS CENTRAL TO OUR WORK AS WE ASK BIG QUESTIONS AND SEEK OUT THE ANSWERS THAT WILL SAVE LIVES FROM BREAST CANCER. WE LEAN ON OUR SCIENTIFIC EXPERTISE AND PATIENT INSIGHTS TO INFLUENCE THE STRATEGY, DESIGN AND CONDUCT OF RESEARCH; TO INVEST IN SCIENCE AND TECHNOLOGY AND SUPPORT THE NEXT GENERATION OF DIVERSE RESEARCH LEADERS, AND TO CONDUCT OUR OWN RESEARCH THAT'S ENGAGING DIVERSE, REAL-WORLD PEOPLE AS OUR PARTNERS IN RESEARCH AND CONTRIBUTING TO THE BODY OF EVIDENCE ABOUT BREAST CANCER. WITH OUR OVER $1.1 BILLION RESEARCH INVESTMENT, KOMEN IS SUPPORTING LABORATORY RESEARCH, TRANSLATIONAL STUDIES, POPULATION SCIENCE AND CLINICAL TRIALS THAT ARE PAVING THE ROAD WITH SCIENTIFIC DISCOVERIES THAT ARE: - UNRAVELLING THE BIOLOGY OF BREAST CANCER, INCLUDING AGGRESSIVE & METASTATIC BREAST CANCERS - LEADING TO THE DEVELOPMENT OF NEW BREAST CANCER DRUGS AND NEW TECHNOLOGIES AND TESTS, - CHANGING THE STANDARD OF BREAST CANCER CARE -ADVANCING PERSONALIZED, PRECISION CARE FOCUSED ON THE PERSON AND THEIR BREAST CANCER AND- PROVIDING NEW, EVIDENCE-BASED INTERVENTIONS TO IMPROVE THE DELIVERY OF THAT CARE. OUR GOAL IS TO IMPROVE HEALTH OUTCOMES FOR EVERYONE AND SAVE LIVES. THROUGH OUR INVESTMENT, KOMEN HAS SUPPORTED MORE THAN 4,200 RESEARCH DISCOVERIES THAT ARE MOVING US CLOSER TO THAT GOAL. THIS INCLUDES OVER 1500 NEW DISCOVERIES FOCUSED ON METASTATIC AND AGGRESSIVE BREAST CANCER, MORE THAN 1,800 POTENTIAL TREATMENTS AND MORE THAN 600 NEW STRATEGIES TO ELIMINATE BREAST CANCER DISPARITIES. THEY INCLUDE ADVANCES SUCH AS NEW BIOMARKERS, NEW DRUG TARGETS, NEW TREATMENTS, AND NEW HEALTH CARE DELIVERY TOOLS. IN PAVING THIS ROAD WITH SCIENTIFIC DISCOVERIES, WE'RE ALSO PAVING IT WITH HOPE. THE HOPE THAT NEW WAYS TO DETECT, DIAGNOSE, TREAT, PREVENT AND, ULTIMATELY, CURE BREAST CANCER ARE AROUND THE CORNER AND THERE WHEN PEOPLE WITH BREAST CANCER NEED THEM TO ALLOW THEM TO LIVE LONGER, WITH IMPROVED QUALITY OF LIFE. TO DATE, 29 DRUGS USED TO TREAT BREAST CANCER HAVE, IN SOME WAY, BEEN SUPPORTED BY KOMEN'S RESEARCH INVESTMENT. KOMEN'S RESEARCH PROGRAMS ARE GUIDED BY MORE THAN 50 OF THE WORLD'S LEADERS IN BREAST CANCER RESEARCH, ONCOLOGY AND ADVOCACY. THE SCIENTIFIC ADVISORY BOARD ASSISTS KOMEN IN SETTING ITS RESEARCH STRATEGY AND PRIORITIZING ITS RESEARCH INVESTMENT. THE KOMEN SCHOLARS LEAD AND PARTICIPATE IN KOMEN'S WORLD-CLASS SCIENTIFIC PEER REVIEW PROCESS. OUR ADVOCATES IN SCIENCE BRING THE COLLECTIVE PATIENT VOICE TO KOMEN'S RESEARCH PROGRAMS AND SCIENTIFIC ACTIVITIES, EMPHASIZING URGENCY AND PATIENT IMPACT. TOGETHER, THIS EXCLUSIVE GROUP OF BREAST CANCER RESEARCHERS, CLINICIANS AND ADVOCATES HELP GUIDE THE ORGANIZATION'S WORK TO SAVE LIVES AND END BREAST CANCER. KOMEN'S TEAM OF HIGHLY QUALIFIED PROFESSIONALS, INCLUDING THOSE WITH PHD-LEVEL EXPERTISE, DEVELOP AND IMPLEMENT KOMEN-LED, PATIENT CENTRIC RESEARCH & SCIENTIFIC PROGRAMS CREATED TO FILL CRITICAL GAPS IN THE SYSTEM AND DRIVE PROGRESS IN UNDERSTUDIED TOPICS AND EMERGING ISSUES IN BREAST CANCER. THE INFLAMMATORY BREAST CANCER (IBC) COLLABORATIVE, BIG DATA FOR BREAST CANCER (BD4BC) INITIATIVE AND SHAREFORCURES PATIENT RESEARCH REGISTRY ARE EXAMPLES OF THE INNOVATIVE AND IMPACTFUL KOMEN-LED PROGRAMS ACTIVE IN FY25. INFLAMMATORY BREAST CANCER (IBC) COLLABORATIVE IN 2016, KOMEN PARTNERED WITH THE INFLAMMATORY BREAST CANCER RESEARCH FOUNDATION AND THE MILBURN FOUNDATION TO LEAD THIS COLLABORATIVE GROUP FOCUSED ON ACCELERATING IBC RESEARCH AND IMPROVING CARE AND OUTCOMES FOR PEOPLE WITH IBC, A DEADLY AND AGGRESSIVE FORM OF CANCER. KOMEN CONVENED PATIENT ADVOCATES, BREAST CANCER RESEARCHERS AND CLINICIANS TO REVIEW THE STATE OF IBC CARE AND RESEARCH GLOBALLY AND PROPOSE SPECIFIC INITIATIVES TO MOVE THE FIELD FORWARD. THE OUTCOME OF THE DISCUSSIONS WAS ABUNDANTLY CLEAR: THE FIELD NEEDS A FORMAL DEFINITION OF IBC. WITHOUT A CLEAR DEFINITION, BOTH PATIENT CARE AND RESEARCH SUFFER. DIAGNOSIS REMAINS SUBJECTIVE AND TREATMENT VARIABLE. THE GOAL IS TO MOVE BEYOND THE SUBJECTIVE 'CLINICAL DIAGNOSIS' TO A SET OF SPECIFIC DIAGNOSTIC CRITERIA AND SCORING SYSTEM THAT WILL ADVANCE IBC RESEARCH AND FACILITATE THE DISCOVERIES THAT WILL IMPROVE THE CARE OF IBC PATIENTS. THE COLLABORATIVE PUBLISHED A PROPOSED DEFINITION OF IBC, BASED ON A REVIEW OF CLINICAL, AND PATHOLOGIC FEATURES IN 2022. THIS EVIDENCE-BASED SCORING SYSTEM IS CURRENTLY BEING VALIDATED (A CRITICAL STEP FOR IT TO BE WIDELY ADOPTED) BY KOMEN-FUNDED RESEARCHERS AT TWO OF THE WORLD'S LEADING IBC CLINICS. IN FY25 KOMEN CREATED AN EASY-TO-USE IBC SCORING SYSTEM ONLINE TOOL TO HELP DOCTORS DIAGNOSE IBC ACCURATELY AND EARLIER. BIG DATA FOR BREAST CANCER KOMEN CONTINUES WORK ON THE BIG DATA FOR BREAST CANCER INITIATIVE, WHICH IS AIMED AT USING BIG DATA TO FUEL SCIENTIFIC DISCOVERIES AND ACCELERATE THE DELIVERY OF EQUITABLE, PATIENT-FOCUSED CARE. KOMEN EMPOWERS BREAST CANCER PATIENTS, ADVOCATES, AND THE PUBLIC WITH INFORMATION AND TOOLS TO MAKE DATA SHARING UNDERSTANDABLE THROUGH THE BIG DATA FOR PATIENTS EDUCATIONAL PROGRAMS. WE ALSO ADDRESS THE CHALLENGES OF INCORPORATING BIG DATA APPLICATIONS INTO BREAST CANCER RESEARCH AND CLINICAL CARE THROUGH WORKING WITH PARTNERS REPRESENTING A VARIETY OF STAKEHOLDERS IN BREAST CANCER RESEARCH AND CLINICAL CARE. ADDITIONALLY, KOMEN SUPPORTS DATA SCIENCE PROJECTS TO IMPROVE BREAST CANCER OUTCOMES AND SAVE LIVES, SUCH AS THE BREAST CANCER HACKATHON CHALLENGE AND KOMEN'S PEOPLE-POWERED BREAST CANCER RESEARCH REGISTRY, SHAREFORCURES. LAUNCHED IN JULY 2023, SHAREFORCURES BUILDS ON KOMEN'S COMMITMENT TO DELIVER THE PROMISE OF BIG DATA TO BREAST CANCER PATIENTS. THIS INVALUABLE BREAST CANCER REGISTRY LEVERAGES THE LATEST TECHNOLOGY AND KOMEN'S BROAD, NATIONAL REACH TO DIRECTLY ENGAGE WITH INDIVIDUALS IMPACTED BY BREAST CANCER WHILE PROVIDING A SAFE, SECURE PATHWAY FOR PEOPLE FROM DIVERSE BACKGROUNDS TO SHARE THEIR HEALTH DATA AND PARTICIPATE IN BREAST CANCER RESEARCH. WITH THIS ROBUST DATA PROVIDED DIRECTLY BY PATIENTS, KOMEN WILL BREAK DOWN SILOS, FUEL SCIENTIFIC DISCOVERIES AND ACCELERATE THE DELIVERY OF EQUITABLE, PATIENT-FOCUSED CARE. MORE THAN 1,000 PEOPLE HAVE SIGNED ON TO PARTICIPATE IN SHAREFORCURES TO DATE. Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED) KOMEN ALSO AWARDS GRANTS TO INDIVIDUAL SCIENTISTS, RESEARCH TEAMS, AND INSTITUTIONS THROUGH A FAIR, TRANSPARENT, RIGOROUS, AND COMPETITIVE REVIEW PROCESS THAT ENSURES MAXIMUM IMPACT FOR OUR RESEARCH INVESTMENT. IN FY25, KOMEN AWARDED 25 GRANTS TO SUPPORT CUTTING-EDGE, IMPACTFUL SCIENTIFIC RESEARCH IN THE UNITED STATES AND ITS TERRITORIES. MOST OF THE GRANTS AWARDED THIS YEAR SUPPORT OUTSTANDING RESEARCH PROJECTS BEING CONDUCTED BY A DIVERSE GROUP OF EARLY CAREER RESEARCHERS, THE NEXT GENERATION OF LEADERS WHO WILL MAKE BREAKTHROUGH DISCOVERIES AND INNOVATIONS TO END BREAST CANCER. THE SUSAN G. KOMEN CAREER TRANSITION AWARDS (CTA) AIM TO HELP OUTSTANDING SENIOR POSTDOCTORAL FELLOWS AND CLINICAL FELLOWS WORKING UNDER THE GUIDANCE OF A MENTOR TO LAUNCH COMPETITIVE, INDEPENDENT RESEARCH CAREERS IN BREAST CANCER. THE CTAS PROVIDE UP TO FIVE YEARS OF RESEARCH FUNDING IN TWO PHASES: PHASE 1 SUPPORTS THE FINAL YEARS OF MENTORED, POSTDOCTORAL TRAINING AND PHASE 2 SUPPORTS THE INDEPENDENT BREAST CANCER-FOCUSED RESEARCH OF THE EARLY CAREER, TENURE-TRACK INVESTIGATORS. CAREER CATALYST RESEARCH (CCR) GRANTS SUPPORT BREAST CANCER RESEARCHERS WHO ARE IN THE EARLY STAGES OF THEIR INDEPENDENT FACULTY CAREERS AND CONDUCTING OUTSTANDING HYPOTHESIS-DRIVEN BASIC, TRANSLATIONAL, CLINICAL AND/OR POPULATION SCIENCE RESEARCH PROJECTS. LEADERSHIP GRANTS SUPPORT KOMEN SCIENTIFIC ADVISORS PURSUING INNOVATIVE RESEARCH PROJECTS WHICH WILL IMPROVE THE UNDERSTANDING, DETECTION, TREATMENT OR PREVENTION OF BREAST CANCER, WITH A FOCUS ON CONQUERING METASTATIC BREAST CANCER, ADVANCING PRECISION MEDICINE AND ELIMINATING BREAST CANCER DISPARITIES. THE 25 RESEARCH GRANTS AWARDED IN FY25 ARE: CAREER TRANSITION AWARDS: DR. CHARLES DAI, OF MASSACHUSETTS GENERAL HOSPITAL, WILL BE EXPLORING A NEW TREATMENT APPROACH FOR TRIPLE NEGATIVE BREAST CANCER (TNBC) BY TARGETING A PROTEIN CALLED THE ANDROGEN RECEPTOR (AR). DR. DAI BELIEVES THAT ACTIVATING AR IN CERTAIN TNBCS COULD HELP FIGHT THE DISEASE BY AFFECTING A CANCER-DRIVING GENE CALLED MYC. THE RESEARCH WILL IDENTIFY WHICH PATIENTS MIGHT BENEFIT AND FIND MARKERS TO PREDICT RESPONSE, POTENTIALLY LEADING TO MORE PERSONALIZED AND EFFECTIVE THERAPIES. DR. AVANTIKA GUPTA, OF MEMORIAL SLOAN KETTERING CANCER CENTER, WILL INVESTIGATE HOW MUTATIONS IN A PROTEIN CALLED APOBEC3 MAY CAUSE BREAST CANCER TO BECOME RESISTANT TO TREATMENT. DR. GUPTA WILL STUDY HOW THESE MUTATIONS AFFECT CANCER CELLS AND LOOK FOR WEAK SPOTS THAT CAN BE TARGETED TO STOP RESISTANCE FROM DEVELOPING. THE FINDINGS COULD LEAD TO NEW WAYS TO KEEP TREATMENTS EFFECTIVE FOR LONGER. DR. ALISSA MICHEL, OF COLUMBIA UNIVERSITY IRVING MEDICAL CENTER, AIMS TO DEVELOP AND TEST TOOLS THAT EMPOWER WOMEN TO MAKE INFORMED DECISIONS ABOUT USING MRI FOR BREAST SCREENING. SHE WILL IDENTIFY FACTORS INFLUENCING ENHANCED MRI SCREENING AMONG HIGH-RISK WOMEN, CONDUCT USABILITY STUDIES FOR PROGRAM REFINEMENT, AND RUN A CLINICAL TRIAL TO BOOST SCREENING AMONG ETHNICALLY AND RACIALLY DIVERSE HIGH-RISK GROUPS. SUCCESS WILL LEAD TO A MULTILEVEL INTERVENTION FOR BREAST CANCER RISK ASSESSMENT, INCORPORATING DECISION SUPPORT FOR BOTH PROVIDERS AND PATIENTS, FACILITATING INTEGRATION INTO CLINICAL WORKFLOWS FOR SUSTAINED OUTREACH TO UNDERSERVED POPULATIONS. DR. VEENA PADMANABAN, OF THE ROCKEFELLER UNIVERSITY, WILL INVESTIGATE HOW BREAST CANCER MAY UTILIZE NEARBY NERVES, KNOWN AS PERIPHERAL NERVES, TO HELP IT SPREAD TO OTHER LOCATIONS. THE RESEARCH WILL UNCOVER HOW BREAST CANCER INTERACTS WITH THE NERVES OF THE NERVOUS SYSTEM AND WHETHER THESE NERVES PLAY A KEY ROLE IN CREATING ENVIRONMENTS WHERE BREAST CANCER CAN GROW AND SPREAD. THE FINDINGS COULD REVEAL NEW WAYS TO STOP BREAST CANCER METASTASIS BY TARGETING THESE NERVE-BREAST CANCER CONNECTIONS. CAREER CATALYST RESEARCH GRANTS: DR. CHUN-KAN CHEN, OF WASHINGTON UNIVERSITY IN ST. LOUIS, AIMS TO FIND NEW WAYS TO CREATE MORE PRECISE AND EFFECTIVE BREAST CANCER VACCINES. DR. CHEN IS EXPLORING WHETHER UNIQUE PIECES OF PROTEIN, MADE FROM SPECIAL CIRCULAR RNA FOUND ONLY IN BREAST CANCER CELLS, CAN BE USED TO TRAIN THE IMMUNE SYSTEM TO BETTER RECOGNIZE AND FIGHT THE DISEASE. IF SUCCESSFUL, THIS RESEARCH COULD LEAD TO MORE PERSONALIZED AND POWERFUL BREAST CANCER TREATMENTS. DR. MIRIAM JACOBS, OF GEORGETOWN UNIVERSITY, IS LEADING A PROJECT THAT AIMS TO BOOST THE BODY'S NATURAL IMMUNE DEFENSES TO FIGHT AN AGGRESSIVE FORM OF BREAST CANCER CALLED TRIPLE NEGATIVE BREAST CANCER (TNBC). BY HELPING IMMUNE CELLS CALLED NATURAL KILLER (NK) CELLS BETTER RECOGNIZE AND ATTACK TNBC, THE RESEARCH COULD LEAD TO NEW TREATMENTS AND A CLINICAL TRIAL FOR WOMEN WITH ADVANCED DISEASE. DR. MARTINA MOLGORA, OF H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, IS DIRECTING A PROJECT THAT EXPLORES THE ROLE OF A PROTEIN CALLED TREM2 IN HOW BREAST CANCER STARTS AND GROWS. DR. MOLGORA WILL STUDY WHETHER TREM2 CAN HELP DETECT, PREDICT, OR TREAT BREAST CANCER, AND HOW IT AFFECTS THE ENVIRONMENT AROUND TUMORS. HER WORK COULD OPEN THE DOOR TO NEW AND MORE EFFECTIVE TREATMENT STRATEGIES. DR. DANIEL O'NEIL, OF YALE UNIVERSITY, WILL IMPLEMENT HOME-BASED CLINICAL BREAST EXAMINATIONS IN SOUTH AFRICA, A COUNTRY WHERE 50% TO 85% OF BREAST CANCER CASES ARE DIAGNOSED AT ADVANCED STAGES DUE TO LIMITED ACCESS TO MAMMOGRAPHY. HE AIMS TO PARTNER WITH LOCAL COMMUNITY HEALTH WORKERS TO DEVELOP METHODS FOR AT-HOME EXAMS, OFFERING A COST-EFFICIENT PATHWAY FOR EARLY DETECTION IN SOUTH AFRICA AND OTHER LOW- AND MIDDLE-INCOME COUNTRIES. DR. CLAIRE SATHE, OF COLUMBIA UNIVERSITY IRVING MEDICAL CENTER, WILL STUDY WORK DISRUPTIONS IN NEWLY DIAGNOSED METASTATIC BREAST CANCER (MBC) PATIENTS, HYPOTHESIZING THEY FACE GREATER JOB LOSS OR REDUCED HOURS THAN THOSE WITH EARLY-STAGE BREAST CANCER. SHE WILL MONITOR NEWLY-DIAGNOSED MBC PATIENTS OVER A THREE-YEAR PERIOD TO ASSESS THE FREQUENCY OF THESE CHANGES AND TO ANALYZE VARIOUS CONTRIBUTING FACTORS, INCLUDING PERSONAL AND JOB-RELATED ISSUES. THE RESEARCH WILL ALSO EVALUATE THE IMPACT OF WORK CHANGES ON HEALTH INSURANCE, TREATMENT INTERRUPTIONS, AND FINANCIAL STRESS, ULTIMATELY SEEKING STRATEGIES TO MITIGATE JOB DISRUPTIONS THAT COULD HINDER CANCER CARE FOR MBC PATIENTS. DR. NA ZHAO, OF BAYLOR COLLEGE OF MEDICINE, IS WORKING ON NEW STRATEGIES TO TREAT TRIPLE NEGATIVE BREAST CANCER (TNBC) LUNG AND LIVER METASTASES. SHE IS INTERESTED IN A PROTEIN INVOLVED IN TRANSLATION, EIF4-A, AND THINKS TARGETING IT IS A POTENTIAL STRATEGY TO TREAT METASTATIC TNBC (MTNBC). ULTIMATELY, SHE HOPES TO INFORM FUTURE CLINICAL TRIALS WITH EIF4-A TARGETING DRUGS AND PAVE THE WAY FOR NOVEL COMBINATION THERAPIES THAT TARGET MTNBC MORE EFFECTIVELY TO IMPROVE PATIENT OUTCOMES. LEADERSHIP GRANTS: DR. ALAN ASHWORTH, OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, WILL CARRY OUT STUDIES TO IDENTIFY AND TEST GENES THAT COULD HELP IMPROVE TWO TYPES OF CANCER TREATMENTS-CAR-T AND NK CELL THERAPIES-FOR ADVANCED BREAST CANCER. MODELS WILL BE USED TO SEE HOW WELL THESE CHANGES WORK AND HOW SAFE THEY ARE. THE GOAL IS TO MAKE THESE TREATMENTS MORE EFFECTIVE, WHICH COULD LEAD TO BETTER OUTCOMES FOR BREAST CANCER PATIENTS. DR. TUYA PAL, OF VANDERBILT UNIVERSITY, WILL CONTINUE PROVIDING WEB-BASED GENETIC COUNSELING TO YOUNG BLACK WOMEN WITH BREAST CANCER, AIMING TO INCREASE GENETIC TESTING TO INFORM THEIR FAMILIES. SHE PLANS TO ENROLL 100 MORE WOMEN AND CONTINUE RESEARCHING GENETIC DRIVERS OF HEREDITARY CANCER BY ANALYZING MEDICAL RECORDS AND SEQUENCING ARCHIVAL TISSUES. THE GOAL IS TO REDUCE DISPARITIES IN BREAST CANCER OUTCOMES THROUGH IMPROVED UNDERSTANDING OF INHERITED MUTATIONS. DR. RULLA TAMIMI, OF WEILL CORNELL, AIMS TO STUDY HOW VARIOUS WEIGHT LOSS METHODS INCLUDING BARIATRIC SURGERY, NUTRITION, AND MEDICATION AFFECT BREAST CANCER RISK AND SURVIVAL IN WOMEN WITH AND WITHOUT THE DISEASE. THIS RESEARCH COULD SIGNIFICANTLY CLARIFY THE IMPACT OF WEIGHT MANAGEMENT STRATEGIES ON BREAST CANCER RISK AND SURVIVAL. DR. KORNELIA POLYAK, OF DANA-FARBER CANCER INSTITUTE, WILL STUDY WHETHER A PROTEIN CALLED MIDKINE CAN BE USED TO HELP IDENTIFY YOUNGER WOMEN AT HIGHER RISK OF DEVELOPING BREAST CANCER. HER GROUP WILL ALSO EXPLORE HOW AN INHERITED GENE MUTATION INCREASES THE CHANCES OF GETTING ESTROGEN RECEPTOR-POSITIVE (ER+) BREAST CANCER AT A YOUNG AGE. THE RESULTS COULD IMPROVE HOW WE ASSESS BREAST CANCER RISK AND LEAD TO NEW WAYS TO PREVENT THE DISEASE IN WOMEN WHO ARE MOST AT RISK. DR. CHRISTINA CURTIS, OF STANFORD UNIVERSITY SCHOOL OF MEDICINE, WILL STUDY THE TISSUE ENVIRONMENT AROUND BREAST CANCER TUMORS IN HIGH-RISK GROUPS TO BETTER UNDERSTAND WHAT CAUSES THE BREAST CANCER TUMOR TO GROW, RESIST TREATMENT, OR COME BACK. BY USING ADVANCED TOOLS, THE RESEARCH AIMS TO IMPROVE HOW PATIENTS ARE GROUPED FOR TREATMENT AND HELP DEVELOP BETTER THERAPIES. Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED) DR. JEFFREY ROSEN, FROM BAYLOR COLLEGE OF MEDICINE, WILL USE COMBINATION THERAPY OF IMMUNE SUPPRESSIVE AGENT WITH EITHER A TUMOR MACROPHAGE ELIMINATOR OR A MODULATOR IN LABORATORY MODELS OF TRIPLE NEGATIVE BREAST CANCER (TNBC). AGENTS IDENTIFIED IN THIS STUDY WILL BE USED IN FUTURE CLINICAL TRIALS TO TARGET LUNG AND LIVER METASTASES IN TNBC. DR. TRACY BATTAGLIA, OF YALE UNIVERSITY, AIMS TO INCREASE GENETIC TESTING FOR HEREDITARY BREAST CANCER, ESPECIALLY AMONG BLACK PATIENTS. HER TEAM IS USING AN AI ALGORITHM TO IDENTIFY ELIGIBLE INDIVIDUALS WITHIN A STATEWIDE CARE NETWORK WHO SHOULD RECEIVE TESTING. THEY WILL IMPLEMENT A SINGLE-ARM PROSPECTIVE PILOT STUDY TO EVALUATE THE INTERVENTION'S EFFECTIVENESS IN INCREASING GENETIC TESTING RATES AMONG APPROXIMATELY 1,200 ELIGIBLE BREAST CANCER PATIENTS. DR. ALLISON KURIAN, AT STANFORD UNIVERSITY SCHOOL OF MEDICINE, WILL EXPLORE WHY SOME WOMEN ARE MORE LIKELY TO DIE FROM BREAST CANCER BY STUDYING DATA FROM THE NORTHERN CALIFORNIA BREAST CANCER FAMILY REGISTRY AND THE CALIFORNIA CANCER REGISTRY. DR. KURIAN WILL BE USING ADVANCED TECHNOLOGIES TO ANALYZE BREAST CANCER TUMORS AND THE AREA AROUND THEM FOR MOLECULAR PATTERNS ASSOCIATED WITH RECURRENCE AND BREAST CANCER DEATH. THE PROJECT WILL LOOK AT HOW FACTORS LIKE RACE, GENETICS, AND THE IMMUNE SYSTEM AFFECT OUTCOMES, WITH THE GOAL OF IMPROVING TREATMENTS AND MAKING CLINICAL TRIALS MORE INCLUSIVE. DR. NANCY LIN, FROM DANA-FARBER CANCER INSTITUTE, WILL USE PATIENT SAMPLES TO FIND NEW TREATMENT TARGETS FOR PEOPLE WITH ADVANCED BREAST CANCER THAT HAS SPREAD TO THE BRAIN AND SPINAL FLUID. THE GOAL IS TO DEVELOP BETTER THERAPIES AND IMPROVE OUTCOMES FOR THESE PATIENTS. DR. BEN PARK, OF VANDERBILT UNIVERSITY MEDICAL CENTER, WILL EXPLORE HOW MUTATIONS IN A PROTEIN CALLED SF3B1 CONTRIBUTE TO BREAST CANCER AND USE THAT KNOWLEDGE TO DEVELOP NEW TREATMENTS FOR TUMORS WITH THIS MUTATION. THE FINDINGS MAY ALSO HELP CREATE THERAPIES FOR OTHER BREAST CANCERS INVOLVING MISTAKES IN PROCESSING GENETIC MESSAGES AND COULD POINT TO NEW DRUG TARGETS. DR. JENNIFER PIETENPOL, FROM VANDERBILT UNIVERSITY MEDICAL CENTER, IS USING PATIENT SAMPLES FROM A CLINICAL TRIAL, ALONG WITH SOME LAB MODELS, TO FIGURE OUT HOW TO BETTER TARGET AND TREAT A TYPE OF TRIPLE NEGATIVE BREAST CANCER CALLED LUMINAL ANDROGEN RECEPTOR (LAR) TNBC. SHE'S EXPLORING HOW A MIX OF ANDROGEN THERAPY AND REGULAR TREATMENTS CAN WORK TOGETHER. THE MAIN AIM IS TO FIND NEW, EFFECTIVE TREATMENTS TAILORED TO LAR, SINCE THIS KIND OF TNBC DOESN'T RESPOND WELL TO IMMUNOTHERAPY. OPPORTUNITY GRANTS: A TEAM LED BY DR. FILIPA LYNCE OF DANA-FARBER CANCER INSTITUTE WILL RECEIVE FUNDING TO FURTHER REFINE AND ENHANCE THE INFLAMMATORY BREAST CANCER (IBC) SCORING SYSTEM, A NOVEL DIAGNOSTIC TOOL ALLOWING CLINICIANS TO BETTER ASSESS THE LIKELIHOOD OF A PATIENT HAVING IBC. IBC IS AN AGGRESSIVE AND DIFFICULT-TO-DIAGNOSE BREAST CANCER WITH HIGHLY VARIABLE SIGNS AND SYMPTOMS. THIS STUDY WILL FURTHER TEST AND OPTIMIZE THE ABILITY OF THE IBC SCORING SYSTEM TO DISCRIMINATE BETWEEN IBC AND NON-IBC IN DIVERSE PATIENT POPULATIONS. MICHELE COTE, PH.D., OF INDIANA UNIVERSITY (IU) WILL RECEIVE FUNDING TO SUPPORT THE SUSAN G. KOMEN TISSUE BANK (KTB) AT THE IU SIMON CANCER CENTER, THE WORLD'S ONLY BIOREPOSITORY OF NORMAL BREAST TISSUE. ACCESS TO THESE NORMAL BREAST TISSUE SAMPLES PROVIDES RESEARCHERS THE OPPORTUNITY TO UNDERSTAND HOW BIOLOGICAL ALTERATIONS IN NORMAL BREAST TISSUE CAN PROMOTE CANCER DEVELOPMENT. ANTONIO WOLFF, M.D., OF JOHNS HOPKINS UNIVERSITY, WILL RECEIVE FUNDING TO SUPPORT THE TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM (TBCRC). THE TBCRC, A GROUP OF 18 LEADING ACADEMIC INSTITUTIONS AND MEDICAL CENTERS, PROVIDES A FORUM WHERE INVESTIGATORS, ADVOCATES, COORDINATORS, SCIENTISTS AND BIOSTATISTICIANS WORK TOGETHER TO PLAN AND REFINE CLINICAL TRIALS, ADVANCING BREAST CANCER RESEARCH. MORE THAN HALF OF TBCRC TRIALS HAVE FOCUSED ON METASTATIC BREAST CANCER. * THE BREAST CANCER ORGANOID WORKSHOP, LED BY ADRIAN LEE, PH.D. AT THE UNIVERSITY OF PITTSBURGH, WILL BRING TOGETHER RESEARCH SCIENTISTS AND PATIENT ADVOCATES TO GUIDE THE NEXT GENERATION OF BREAST CANCER ORGANOID RESEARCH BY SHARING KNOWLEDGE AND EXPERIENCE IN INNOVATIVE TECHNOLOGIES, PROTOCOLS, TECHNIQUES, AND BARRIERS TO PROGRESS. ORGANOIDS ARE A THREE-DIMENSIONAL MODEL RECAPITULATING THE FUNCTIONAL, STRUCTURAL, AND BIOLOGICAL COMPLEXITY OF AN ORGAN OR TUMOR. * ORGANOIDS SERVE AS A POWERFUL TOOL FOR MODELING HUMAN DISEASES. ORGANOIDS ARE A UNIQUE AND VALUABLE RESOURCE FOR PRE-CLINICAL DRUG SCREENING TO IMPROVE PATIENT OUTCOMES THROUGH PRECISION MEDICINE. EDUCATION KOMEN IS A TRUSTED SOURCE OF BREAST CANCER INFORMATION FOR PEOPLE ALL OVER THE WORLD AND IS INSTRUMENTAL IN CONNECTING PEOPLE WITH THE RESOURCES THEY NEED. OUR GOAL IS TO EMPOWER PEOPLE TO MAKE INFORMED BREAST CARE DECISIONS. OUR WEBSITE, KOMEN.ORG, PROVIDES CURRENT, SAFE, ACCURATE, COMPREHENSIVE, AND UNBIASED INFORMATION ABOUT BREAST CANCER, BASED ON SCIENTIFIC EVIDENCE. CONTENT IS OFFERED IN A VARIETY OF FORMATS INCLUDING INTERACTIVE VIDEO USING ANIMATION AND VOICEOVER IN ENGLISH AND SPANISH, INTERACTIVE 3D MODELS, ILLUSTRATIONS, CHARTS, GRAPHS, AND SHORT VIDEOS TO MEET THE LEARNING PREFERENCES AND NEEDS OF OUR WEB VISITORS. THE ABOUT BREAST CANCER PAGES AND PORTIONS OF THE PATIENT & CAREGIVER SECTIONS OF KOMEN'S WEBSITE, ARE CO-DEVELOPED WITH HARVARD MEDICAL SCHOOL FACULTY AND DANA-FARBER/HARVARD CANCER CENTER STAFF AND HAD ABOUT 3 MILLION USERS IN FY25. WHETHER A NEW THERAPY OR TEST BECOMES PART OF THE STANDARD OF CARE FOR BREAST CANCER DEPENDS LARGELY ON CLINICAL TRIAL RESULTS. KOMEN USED THE CLINICAL TRIALS EDUCATION INITIATIVE ON KOMEN.ORG TO EDUCATE PEOPLE ABOUT THE IMPORTANCE OF CLINICAL TRIALS AND THE NEED FOR DIVERSITY OF STUDY PARTICIPANTS TO RELFECT THE DIVERSITY OF PEOPLE DIAGNOSED WITH BREAST CANCER, TO EMPOWER PEOPLE WITH INFORMATION ON TRIALS AND RESOURCES, AND TO OFFER PERSONALIZED SUPPORT AVAILABLE THROUGH THE KOMEN BREAST CARE HELPLINE. THE RESOURCES HELP TO ENSURE PATIENTS ARE EQUIPPED TO MAKE INFORMED DECISIONS REGARDING TRIAL PARTICIPATION IN PARTNERSHIP WITH THEIR HEALTH CARE PROVIDERS. THE INITIATIVE ALSO RAISES AWARENESS OF THE DIFFERENT TYPES OF TRIALS, INCLUDING TRIALS SUPPORTED BY KOMEN FOCUSED ON RISK, SCREENING AND EARLY DETECTION, TREATMENT, FAMILY SUPPORT, QUALITY OF LIFE AND SURVIVORSHIP. KOMEN PROVIDES EVIDENCE-BASED, EASY-TO-READ EDUCATIONAL MATERIALS IN DOWNLOADABLE FORMATS ON KOMEN.ORG. EXAMPLES OF KOMEN EDUCATIONAL MATERIALS INCLUDE: A) BREAST SELF-AWARENESS MESSAGE RESOURCES IN MORE THAN 40 LANGUAGES, B) BREAST CANCER-SPECIFIC BROCHURES AND FACT SHEETS, C) BOOKLETS WITH SUPPORT INFORMATION FOR SURVIVORS AND CO-SURVIVORS, AND D) QUESTIONS TO ASK YOUR DOCTOR MATERIALS. NBCAM BREAST HEALTH IQ EVENT - IN FY25, IN HONOR OF BREAST CANCER AWARENESS MONTH, WE LAUNCHED OUR BREAST HEALTH IQ CHALLENGE. THIS FUN AND EDUCATIONAL TRIVIA SHOW TESTED KNOWLEDGE ABOUT BREAST CANCER RISK FACTORS AND EARLY DETECTION AND OFFERED PROACTIVE BREAST CARE TIPS. EDUCATIONAL GOALS FOCUSED ON UNDERSTANDING PERSONAL RISK TO EMPOWER PEOPLE TO MAKE IMPORTANT DECISIONS AND TAKE ACTION FOR THEIR HEALTH. BREAKTHROUGHS IN BREAST CANCER SERIES: A VIRTUAL, SHAREABLE EDUCATION SERIES IN PARTNERSHIP WITH INDUSTRY EXPERTS, SCIENTISTS FROM ACADEMIC INSTITUTIONS AND PATIENT ADVOCATES WHO CAN DIRECTLY SPEAK TO CLINICAL RESEARCH AND NEW THERAPEUTICS. GUIDED BY THESE EXPERTS, KOMEN SHARES COMPLEX SCIENTIFIC TOPICS IN AN APPROACHABLE, HEADLINE-FOCUSED FORMAT THAT IS COMPELLING, INTERESTING AND UNDERSTANDABLE TO PATIENTS AND CAREGIVERS. IN FY25 THERE WERE 4 EPISODES OF BREAKTHOUGHS IN BREAST CANCER. KNOW MORE: THE KNOW MORE EDUCATION SERIES PROVIDES PATIENTS WITH A COLLECTION OF EVERGREEN, ACCESSIBLE, EDUCATIONAL CONTENT THAT GRADUALLY BUILDS FOUNDATIONAL KNOWLEDGE, NO MATTER THEIR LEARNING STYLES. EACH MONTH, THE SERIES HIGHLIGHTS A CRITICAL LEARNING TOPIC THROUGH A MULTI-MEDIA FORMAT TO EDUCATE THE BREAST CANCER COMMUNITY. IN FY25 THERE WERE 8 INSTALLMENTS OF THE KNOW MORE SERIES. CLINICAL TRIAL SPOTLIGHT SERIES: KOMEN'S SPOTLIGHT ON CLINICAL TRIALS IS A PATIENT EDUCATION SERIES THAT EQUIPS PEOPLE WITH INFORMATION TO SUPPORT INFORMED DECISIONS ABOUT THEIR MEDICAL OPTIONS, IN PARTNERSHIP WITH THEIR DOCTORS. THROUGH THIS SERIES, KOMEN TEACHES BREAST CANCER PATIENTS HOW TO ADVOCATE FOR THEMSELVES, GET CONNECTED WITH CLINICAL TRIALS AND HEAR STORIES FROM THOSE WHO HAVE PARTICIPATED IN CLINICAL TRIALS. IN FY25, THERE WERE 9 SPOTLIGHTS PUBLISHED. Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED) KOMEN CONTINUED TO SUPPORT THE METASTATIC BREAST CANCER (MBC) COMMUNITY BY HOSTING 10 VIRTUAL EVENTS THROUGH THE MBC IMPACT SERIES AND 2 IN PERSON EVENTS IN PHILADELPHIA AND SEATTLE. THESE EVENTS PROVIDED PEOPLE LIVING WITH METASTATIC BREAST CANCER AND THEIR LOVED ONES A SAFE, COLLABORATIVE SPACE TO GATHER INFORMATION AND DISCOVER PRACTICAL RESOURCES TO HELP MAKE DECISIONS FOR IMPROVED PHYSICAL AND EMOTIONAL HEALTH. WE OFFER ON-DEMAND VIDEOS OF THESE EVENTS IN BOTH ENGLISH AND SPANISH FOR THOSE NOT ABLE TO ATTEND LIVE. THE MBC IMPACT SERIES ALSO OFFERS REGULAR NEWSLETTERS AND 3 EPISODES OF WELLNESS WEDNESDAY VIDEOS FOCUSED ON QUALITY OF LIFE AND OVERALL WELLNESS TOPICS. PATIENT SUPPORT KOMEN IS COMMITTED TO ELIMINATING BREAST HEALTH DISPARITIES AND ENSURING ALL PEOPLE HAVE ACCESS TO THE HIGH-QUALITY CARE THEY NEED. THROUGHOUT OUR HISTORY, WE HAVE HELPED REMOVE FINANCIAL, GEOGRAPHIC, AND CULTURAL BARRIERS TO CARE, AND WE CONTINUE TO EVOLVE OUR PATIENT CARE MODEL TO MEET THE NEEDS OF BREAST CANCER PATIENTS TODAY. THE KOMEN PATIENT CARE CENTER (PCC) PROVIDES INDIVIDUALIZED, DIRECT PATIENT CARE AND SUPPORT ACROSS THE BREAST HEALTH CONTINUUM THROUGH A NATIONAL TELEHEALTH MODEL. KOMEN'S TEAM OF PATIENT NAVIGATORS ARE THE ENGINE BEHIND OUR PATIENT CARE CENTER. OUR PATIENT NAVIGATORS, WHO ARE INFORMED BY EVIDENCE-BASED INTERVENTIONS, HELP BREAK DOWN BARRIERS TO CARE BY GUIDING PATIENTS THROUGH NUMEROUS DECISIONS, APPOINTMENTS AND TREATMENT OPTIONS. THEY STAY WITH PATIENTS FOR AS LONG AS NEEDED, FROM DAYS TO MONTHS, ENSURING ALL PATIENTS HAVE ACCESS TO THE RESOURCES AND CARE THEY NEED. ACCESSED THROUGH THE KOMEN BREAST CARE HELPLINE, THE PCC PROVIDED NEARLY 43,000 SERVICES TO NEARLY 36,000 PEOPLE THIS YEAR, INCLUDING: PROVIDING INFORMATION AND EDUCATIONAL RESOURCES ABOUT BREAST CANCER SCREENING AND TREATMENT OPTIONS. HELP WITH UNDERSTANDING A BREAST CANCER DIAGNOSIS. CONNECTIONS TO RESOURCES AND FINANCIAL SUPPORT. EMOTIONAL SUPPORT. ANOTHER IMPORTANT TOOL FOR KOMEN'S NAVIGATORS IS THE KOMEN FINANCIAL ASSISTANCE PROGRAM (KFA), WHICH ADDRESSES FINANCIAL BARRIERS TO CARE. WHILE MEDICAL TREATMENT AND MEDICAL CARE ARE THE PRIMARY COSTS ASSOCIATED WITH BREAST CANCER, THERE ARE OTHER COSTS OF DAILY LIVING THAT MAY PREVENT BREAST CANCER PATIENTS FROM COMPLETING TREATMENT. THE KFA HELPS INDIVIDUALS IN BREAST CANCER TREATMENT OR THOSE LIVING WITH METASTATIC BREAST CANCER (MBC), WHO HAVE AN ANNUAL INCOME AT OR BELOW 300% OF THE FEDERAL POVERTY LEVEL, PAY FOR COSTS ASSOCIATED WITH BASIC NEEDS LIKE HOUSING, TRANSPORTATION, GROCERIES, MEDICATIONS, CHILDCARE AND MORE. OVER 17,000 PEOPLE WERE SUPPORTED WITH NEARLY $7.5 MILLION IN FINANCIAL SUPPORT THROUGH KFA THIS YEAR. BY COVERING NECESSARY OUT-OF-POCKET COSTS, THE KFA INCREASES THE CHANCES THAT PEOPLE WILL CONTINUE WITH THEIR CARE, THEREBY DRIVING BETTER OUTCOMES. THE KOMEN PCC TEAM IS MADE UP OF MORE THAN 30 HIGHLY SKILLED PROFESSIONALS WHO ARE AS DIVERSE AS THOSE WE SERVE. OUR CARING AND COMPASSIONATE TEAM INCLUDES PATIENT NAVIGATORS, SOCIAL WORKERS, BILINGUAL SPECIALISTS, AND BREAST CANCER SURVIVORS FROM AROUND THE COUNTRY WHO UNDERSTAND THAT EVERYONE'S HEALTH CARE JOURNEY IS UNIQUE, THUS PROVIDING INDIVIDUALIZED CARE TO ENSURE THE BEST POSSIBLE OUTCOMES FOR EACH PERSON. KOMEN'S PCC MAKES CERTAIN THAT NO ONE FACES BREAST CANCER ALONE. WE ARE COMMITTED TO ADDRESSING BREAST HEALTH DISPARITIES THROUGH OUR TEAM OF EXPERTS BY MEETING PATIENTS WHERE THEY ARE AND HELPING THEM ACCESS HIGH-QUALITY BREAST CARE NO MATTER WHERE THEY LIVE AND FOR AS LONG AS THEY NEED IT. PUBLIC POLICY AND ADVOCACY SUSAN G. KOMEN IS THE NONPARTISAN VOICE FOR OVER 4 MILLION BREAST CANCER SURVIVORS, INDIVIDUALS LIVING WITH THE DISEASE AND THEIR SUPPORTERS ACROSS THE UNITED STATES. THROUGH OUR CENTER FOR PUBLIC POLICY, KOMEN WORKS TO EDUCATE PEOPLE ABOUT PUBLIC POLICY ISSUES SO THEY ARE EMPOWERED TO BECOME FORCEFUL ADVOCATES FOR THEMSELVES AND THEIR NEIGHBORS AND THEN UNITES THEIR COLLECTIVE VOICES FOR MAXIMUM IMPACT THE CENTER FOR PUBLIC POLICY IS THE DRIVING FORCE THAT ENSURES THE VOICE OF BREAST CANCER PATIENTS, SURVIVORS, CAREGIVERS, AND OTHER MEMBERS OF THE BREAST CANCER COMMUNITY ARE HEARD BY POLICYMAKERS ON LOCAL, STATE AND NATIONAL LEVELS., KOMEN BELIEVES THAT ONLY THROUGH INFORMED GOVERNMENT ACTION CAN BROAD, SYSTEMIC AND LASTING CHANGES BE MADE TO ENSURE THE NEEDS OF THE BREAST CANCER COMMUNITY ARE MET. KOMEN'S 2024-2025 POLICY AND ADVOCACY PRIORITIES INCLUDED: ACCELERATING RESEARCH BY SUPPORTING INCREASED STATE AND FEDERAL FUNDING FOR BREAST CANCER RESEARCH AND INCREASED CLINICAL TRIAL ACCESSIBILITY; EXPANDING ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL PATIENT POPULATIONS; SUPPORTING STATE AND FEDERAL FUNDING FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S (CDC) NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM (NBCCEDP); ADVOCATING FOR STATE AND FEDERAL POLICIES TO REMOVE ADMINISTRATIVE BURDEN AND FINANCIAL BARRIERS TO SCREENING, DIAGNOSIS, AND TREATMENT; INCLUDING THOSE THAT WOULD REQUIRE ORAL PARITY, PREVENT THE USE OF STEP THERAPY PROTOCOLS AND ELIMINATE OUT-OF-POCKET COSTS FOR MEDICALLY NECESSARY DIAGNOSTIC AND SUPPLEMENTAL BREAST IMAGING. IN ADDITION TO THE STATE AND FEDERAL WORK ON OUR POLICY AND ADVOCACY PRIORITIES, KOMEN ALSO ENGAGED ON ISSUES RELATED TO CUSTOM BREAST PROSTHESES, GENETIC AND GENOMIC TESTING, MEDICARE AND SOCIAL SECURITY DISABILITY INSURANCE (SSDI) WAITING PERIODS, MULTICANCER EARLY DETECTION TESTS, PALLIATIVE CARE, SURPRISE MEDICAL BILLING AND SURVIVORSHIP. KOMEN DEVELOPED AND IMPLEMENTED ADVOCACY CAMPAIGNS TO ENCOURAGE LAWMAKERS AND AGENCY OFFICIALS TO SUPPORT AND IMPLEMENT PROGRAMS THAT WOULD ADVANCE OUR PRIORITY ISSUES. KOMEN CONTINUED TO RECRUIT AND ENGAGE ADVOCATES TO FURTHER STRENGTHEN ITS GRASSROOTS ADVOCACY NETWORK. Form 990, Part VI, Line 1a Executive Committee THE ORGANIZATION'S BYLAWS PROVIDE FOR AN EXECUTIVE COMMITTEE COMPRISED OF A MINIMUM OF THREE MEMBERS INCLUDING THE BOARD CHAIR, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND ADDITIONAL BOARD MEMBERS, AS RECOMMENDED BY THE GOVERNANCE COMMITTEE AND APPOINTED BY THE BOARD OF DIRECTORS. MEMBERS OF THE EXECUTIVE COMMITTEE MUST EITHER BE DIRECTORS OF THE ORGANIZATION OR THE PRESIDENT AND CHIEF EXECUTIVE OFFICER. THE BYLAWS PROVIDE THE EXECUTIVE COMMITTEE WITH THE AUTHORITY TO: (A) APPOINT MEMBERS TO NON-STANDING COMMITTEES OF THE ORGANIZATION, AND NAME CHAIRS OF SUCH COMMITTEES; (B) AUTHORIZE UNBUDGETED DISBURSEMENTS BY THE ORGANIZATION IN ACCORDANCE WITH THE SPECIFIC EXPENDITURE AUTHORITY PRESCRIBED BY THE BOARD OF DIRECTORS; (C) EMPLOY AGENTS; AND (D) CARRY INTO EXECUTION SUCH OTHER MEASURES AS IT DETERMINES WILL PROMOTE THE PURPOSE OF THE ORGANIZATION. THE COMMITTEE ALSO MAY EXERCISE, WHEN THE BOARD IS NOT IN SESSION, ALL OF THE AUTHORITY OF THE BOARD IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE ORGANIZATION WITH CERTAIN EXCEPTIONS SUCH AS REPEALING ANY BOARD RESOLUTIONS, AMENDING THE ORGANIZATION'S ARTICLES OR BYLAWS, OR MERGING OR DISSOLVING THE ORGANIZATION. THIS DELEGATION DOES NOT RELIEVE THE BOARD OF ANY OF ITS RESPONSIBILITIES IMPOSED BY LAW, AND THE COMMITTEE ENDEAVORS TO LIMIT ITS EXERCISE OF AUTHORITY TO TIME SENSITIVE ISSUES. Form 990, Part VI, Line 15 OFFICES & POSITIONS FOR WHICH PROCESS WAS USED, & YEAR PROCESS WAS BEGUN THE HUMAN CAPITAL MANAGEMENT COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2009 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2023, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION. Form 990, Part VI, Line 4 Significant changes to organizational documents On September 17, 2024 the Board of Directors unanimously approved a motion to the proposed changes to the Seventh Amended and Restated Bylaws and adopted the Eighth Amended and Restated Bylaws as presented. The change to Section 3.04 added a third, 3-year term for Class II directors. On March 26, 2025, the Board of Directors unanimously approved a motion to amend the current Eighth Amended Bylaws to adopt the Ninth Amended Bylaws. The changes to the bylaws included the removal of Section 5.04 to effectively eliminate the Development Committee. Form 990, Part VI, Line 11b Review of form 990 by governing body MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE OF AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVEL MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR SUBSEQUENT PRESENTATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWS, MAKES RECOMMENDATIONS, AND APPROVES THE FORM 990 FOR PRESENTATION TO THE BOARD OF DIRECTORS. THEREAFTER, THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE FORM 990 PRIOR TO FILING. Form 990, Part VI, Line 12c Conflict of interest policy KOMEN'S CONFLICT OF INTEREST POLICY REQUIRES EVERY BOARD MEMBER, OFFICER, DIRECTOR, COMMITTEE MEMBER, ADVISORY BOARD MEMBER, EMPLOYEE, AND VOLUNTEER TO AVOID CONFLICTS OF INTEREST. IT ALSO REQUIRES THESE PERSONS TO REPORT ANY ACTUAL AND/OR POTENTIAL CONFLICTS OF INTEREST AS SOON AS POSSIBLE. REPORTS ARE REVIEWED BY THE GENERAL COUNSEL'S OFFICE AND/OR INTERNAL AUDIT, AND APPROPRIATE ACTION IS TAKEN PURSUANT TO THE CONFLICT OF INTEREST POLICY. FURTHER, KOMEN REQUIRES ALL BOARD MEMBERS, OFFICERS, DIRECTORS, COMMITTEE MEMBERS, ADVISORY BOARD MEMBERS, AND EMPLOYEES TO REVIEW AND EXECUTE THE CONFLICT OF INTEREST POLICY ANNUALLY AND DISCLOSE ANY ADDITIONAL ACTUAL/POTENTIAL CONFLICTS OF INTEREST. THESE ANNUAL DISCLOSURES ARE REVIEWED IN THE SAME MANNER. THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS RECEIVES AND REVIEWS ALL REPORTED ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AND THE RELATED ACTION TO ADDRESS THEM. Form 990, Part VI, Line 19 Required documents available to the public KOMEN'S FINANCIAL STATEMENTS AND THE FORM 990 ARE PUBLICLY AVAILABLE ON OUR WEBSITE. THE CONFLICT OF INTEREST POLICY IS ALSO AVAILABLE ON OUR WEBSITE. THE CERTIFICATE OF FORMATION IS AVAILABLE FROM THE TEXAS SECRETARY OF STATE AND OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE AS REQUIRED BY STATE LAW. FORM 1023 IS NOT PUBLISHED ONLINE BUT IS AVAILABLE TO THE PUBLIC UPON REQUEST. Form 990, Part IX, Line 1 FOR OVER 40 YEARS, SUSAN G. KOMEN HAS WORKED TO FULFILL ITS VISION OF CREATING A WORLD WITHOUT BREAST CANCER THROUGH ITS MISSION OF SAVING LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAKTHROUGH RESEARCH TO BETTER DETECT, PREVENT, TREAT BREAST CANCERS. OVER THE LAST THREE YEARS, KOMEN CONTINUED TO IMPLEMENT A SERIES OF CHANGES BEGUN IN 2020 TO STRENGTHEN ITS FINANCIAL AND OPERATIONAL POSITION IN RESPONSE TO THE CHANGING NEEDS OF THE BREAST CANCER COMMUNITY AND ECONOMIC CONDITIONS RESULTING FROM THE COVID-19 PANDEMIC. KOMEN HAS NEARLY COMPLETED THE CONSOLIDATION OF ALL OPERATIONS OF ITS INDEPENDENT AFFILIATES INTO ITS HEADQUARTERS ORGANIZATION, RESULTING IN A SINGLE ORGANIZATION. THIS CONSOLIDATION IS ENABLING KOMEN TO LEVERAGE THE COMBINED EXPERTISE OF ITS MISSION LEADERS TO DELIVER A UNITED MISSION PROGRAM, UTILIZING TECHNOLOGY AS A KEY DRIVER TO CONNECT TO PEOPLE WHO NEED TO ACCESS CARE WHERE THEY ARE AND TO HELP IMPROVE THE PATIENT EXPERIENCE, AS WELL AS RESULTED IN ADMINISTRATIVE AND OPERATIONAL EFFICIENCIES. CENTRAL TO KOMEN'S VISION IS A STEADFAST COMMITMENT TO INVESTING IN BREAKTHROUGH RESEARCH. KOMEN REMAINED COMMITTED TO INVESTING IN RESEARCH CENTERED ON THE PRIMARY FOCUS OF METASTATIC BREAST CANCER AND UNDERSTANDING AND ELIMINATING DISPARITIES IN BREAST CANCER OUTCOMES BETWEEN BLACK AND WHITE PATIENTS. DESPITE THE ECONOMIC UNCERTAINTY AND CHALLENGING FUNDRAISING ENVIRONMENT, KOMEN AWARDED $40 MILLION IN NEW RESEARCH AWARDS OVER THE PAST TWO FISCAL YEARS. WHILE WE CONTINUE TO INVEST IN RESEARCH INTO NEW TREATMENTS, KOMEN SUPPORTS PEOPLE WHO ARE FACING BREAST CANCER TODAY THROUGH A GROWING SUITE OF PATIENT CARE SERVICES, INCLUDING DIRECT FINANCIAL ASSISTANCE THROUGH ITS TREATMENT ASSISTANCE PROGRAM, ELIGIBLE TO HELP PAY FOR EXPENSES THAT MAY SERVE AS A BARRIER TO ATTAINING THE CARE NEEDED TO SURVIVE, SUCH AS CO-PAYS, TRANSPORTATION, CHILDCARE OR RENT. Form 990, Part XI, Line 9 Other changes in net assets or fund balances RESCINDED GRANTS - 1105316; Other Expense - 125; Total - 1105441;